Lexaria Bioscience Corp.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 100 - 740 MCCURDY ROAD, KELOWNA, A1, V1X 2P7
Mailing Address 100 - 740 MCCURDY ROAD, KELOWNA, A1, V1X 2P7
Phone 250-765-6424
Fiscal Year End 0831
EIN 202000871
Financial Overview
FY2025 FY
$706K
Revenue
$8.04M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 10-Q Quarterly financial report | January 13, 2026 | View on SEC |
| S-1 IPO registration statement | December 29, 2025 | View on SEC |
| S-3 Shelf registration for future offerings | December 29, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 16, 2025 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | December 10, 2025 | View on SEC |
| S-1/A IPO registration amendment | December 5, 2025 | View on SEC |
| 10-K Annual financial report | November 28, 2025 | View on SEC |
Annual Reports
10-K November 28, 2025
- DehydraTECH improved drug absorption in hypertension studies, outperforming current methods.
- Signed partnerships with Altria and a generic drugmaker to explore DehydraTECH applications.
Material Events
8-K Financial Distress February 6, 2026
High Impact
- Lexaria Bioscience is a biotech company focused on innovation.
- Develops the DehydraTECH™ drug delivery platform.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.